卵巢癌的二次细胞减少手术与第二次白金敏感复发:一个多中心回顾性队列研究
Yuxi Zhao1, Zhihao Jiang2, Tao Guo1
1Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
概括
对于敏感性复发性卵巢癌的二次细胞还原手术 (SCS) 提供了可比的生存结果,无论是在第一次还是第二次复发时进行. 这种手术干预是安全和有效的,可以改善患者的生存率.
科学领域:
- 妇科瘤学 妇科瘤学
- 手术瘤学手术瘤学
- 临床癌症研究 临床癌症研究
背景情况:
- 卵巢癌复发通常与敏感性疾病有关,需要有效的治疗策略.
- 二次细胞还原手术 (SCS) 是复发性卵巢癌的潜在治疗选择.
- 在敏感性复发性卵巢癌 (PSR) 中SCS的最佳时间仍然是研究的主题.
研究的目的:
- 为了比较卵巢癌患者的生存结果,在第一次接受SCS时与第二次敏感复发相比.
- 根据复发时间来评估SCS的安全性和有效性.
主要方法:
- 一项多中心回顾性队列研究,涉及231名卵巢癌患者.
- 患者在第一个 (第1组,n=175) 或第二个 (第2组,n=56) 敏感复发时接受了SCS.
- 总体存活率 (OS) 和第二次进展时间 (PFS2) 进行了比较;术后并发症使用克拉维恩-丁多分类来评估.
主要成果:
- 在两组中,完整切除率都很高 (第一组为84.0%,第二组为78.6%).
- 术后并发症的发生率在两组之间相似.
- 在第一组中没有达到中位数的生存期,而在第二组中为77.3个月,表明了可比的生存结果.
- 完整和最佳切除独立地与改善的生存率有关.
结论:
- 二次细胞还原手术 (SCS) 是对敏感性复发性卵巢癌的安全有效治疗方法.
- 无论是第一次还是第二次复发时,SCS的时间不会显著影响生存结果.
- 在SCS期间实现完整或最佳的瘤切除对于改善患者存活率至关重要.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
2.5K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...